Talphera (TLPH) Liabilities and Shareholders Equity (2010 - 2026)
Talphera (TLPH) recorded quarterly Liabilities and Shareholders Equity of $30.2 million in Q1 2026, up 1.47% quarter-over-quarter from $29.7 million in Q4 2025, and up 101.1% on a YoY basis from $15.0 million in Q1 2025.
Talphera (TLPH) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Talphera's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $30.2 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 101.1% year-over-year to $30.2 million; the TTM figure through Mar 2026 stood at $107.1 million (up 35.44% YoY), while the FY2025 annual figure was $29.7 million, up 62.97% from the prior year.
- Liabilities and Shareholders Equity was $30.2 million for Q1 2026 at Talphera, up from $29.7 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $72.0 million in Q1 2022 to a low of $15.0 million in Q1 2025.
- Historically, Liabilities and Shareholders Equity has averaged $31.0 million across 5 years, with a median of $26.3 million in 2023.
- The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity tumbled 68.42% in 2023, then jumped 101.1% in 2026.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $47.5 million in 2022, then sank by 57.05% to $20.4 million in 2023, then dropped by 10.59% to $18.2 million in 2024, then jumped by 62.97% to $29.7 million in 2025, then climbed by 1.47% to $30.2 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $30.2 million (Q1 2026), $29.7 million (Q4 2025), and $30.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 2.27 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.35 Bn |
| 10 | Talphera | 56.42 Mn | 56.42 Mn | - | 30.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.16 Mn |
| Dec 31, 2025 | 29.72 Mn |
| Sep 30, 2025 | 30.74 Mn |
| Jun 30, 2025 | 16.52 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | 18.24 Mn |
| Sep 30, 2024 | 21.01 Mn |
| Jun 30, 2024 | 24.86 Mn |
| Mar 31, 2024 | 28.77 Mn |
| Dec 31, 2023 | 20.40 Mn |
| Sep 30, 2023 | 23.26 Mn |
| Jun 30, 2023 | 17.73 Mn |
| Mar 31, 2023 | 26.29 Mn |
| Dec 31, 2022 | 47.49 Mn |
| Sep 30, 2022 | 48.31 Mn |
| Jun 30, 2022 | 56.13 Mn |
| Mar 31, 2022 | 71.97 Mn |
| Dec 31, 2021 | 77.89 Mn |
| Sep 30, 2021 | 72.26 Mn |
| Jun 30, 2021 | 79.59 Mn |